Citius Oncology, Inc.(CTOR) - 2025 Q2 - Quarterly Results

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 LYMPHIR commercial availability planned for the fourth quarter of 2025 $12.5 million in gross financings raised during the quarter by Citius Pharmaceuticals, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction CRANFORD, N.J., August 12, 2025 -- Citius Oncology, Inc. ("Citius Oncology" or the ...